Men with Low-Risk Prostate Cancer Face Lower All-Cause Mortality vs. Cancer-Free Men
the Cancer Therapy Advisor take:
Men with low-risk prostate cancer (PCa) face lower all-cause mortality compared to PCa-free men due to lower cardiovascular mortality.
Additionally, men with intermediate or high risk face substantial death risk regardless of Charlson comorbidity index (CCI).
These results were part of a recent study published in BJU International which looked at patient data gathered from PCBase Sweden. Mieke van Hemelrijck, PHD, and fellow researchers at King’s College London in the UK observed 57,187 men diagnosed with localized PCa between 1997 to 2009 as well as 114,374 age- and county-matched PCa-free control men.
They found that in men with low-risk PCa, all-cause mortality after 10 years was 18 percent compared to corresponding men without PCa who were at 21 percent, with 31 percent of patients dying from CVD compared to 37 percent, respectively.
In low-risk men, PCa was the third most common cause of death after cardiovascular disease and other cancers. In men with intermediate and high-risk localized PCa, their disease was the most common cause of death.
Men with low-risk PCa face lower all-cause mortality compared to PCa-free men.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Resveratrol and Cancer
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer
- Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy
- Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer
- Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling